-

01:19:54 AM

Latest RLFTF Stock Market News

RLFTF - RELIEF THERAPEUTICS Holding AG

11/23/20 1:20 AM

OTC : RLFTF

Relief Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding AG

RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) (" Relief" or the " Company"), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today gives

RHEA-AI

neutral

11/13/20 1:35 AM

OTC : RLFTF

clinical trialcovid-19

Relief, with Partner NeuroRx, Announces Enrollment of 150 Patients in Phase 2b/3 Trial of RLF-100(TM) for Critical COVID-19 with Respiratory Failure

RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("

RHEA-AI

neutral

11/04/20 1:40 AM

OTC : RLFTF

management

Relief Appoints J. Paul Waymack, M.D., Sc.D. as Consultant to Strengthen Management Team

RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) (" Relief" or the " Company"), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today announced

RHEA-AI

very positive

10/13/20 1:00 AM

OTC : RLFTF

covid-19

NeuroRx and Relief announce topline efficacy data from patients treated with RLF-100™ (aviptadil) under the U.S. FDA Expanded Access Protocol authorization for respiratory failure related to critical COVID-19

RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (" Relief" or the " Company") and NeuroRx, Inc., today announced topline results from 45 patients assessed in an open-label prospective study where 21 patients admitted to an intensive care

RHEA-AI

neutral

10/08/20 1:10 AM

OTC : RLFTF

management

Relief Therapeutics Appoints Industry Veteran, Jack Weinstein, as Chief Financial Officer and Treasurer

RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) (" Relief" or the " Company"), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today announced the

RHEA-AI

neutral

09/30/20 1:00 AM

OTC : RLFTF

NeuroRx and Relief Therapeutics Establish Supply and Distribution Agreements for RLF-100™ (aviptadil)

RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (" Relief" or the " Company") and NeuroRx, Inc. have established supply chain agreements and ordered sufficient drug substance (RLF-100 TM) to prepare to treat 1 million patients with

RHEA-AI

neutral

09/28/20 1:30 AM

OTC : RLFTF

Relief Announces Capital Increase from its Final Tranche of the Share Subscription Facility with GEM

RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) (" Relief" or the " Company"), a biopharmaceutical company with its lead compound

RHEA-AI

neutral

09/23/20 1:00 AM

OTC : RLFTF

covid-19

NeuroRx submits request for Emergency Use Authorization for RLF-100™ (aviptadil) in the treatment of patients with Critical COVID-19 and Respiratory Failure who have exhausted approved therapy

NeuroRx, Inc. has submitted a request for an Emergency Use Authorization (EUA) with the US FDA for the use of RLF-100™ aviptadil in patients who are receiving intensive care and who have exhausted all approved treatments. RLF-100 is being developed by

RHEA-AI

neutral

09/21/20 1:00 AM

OTC : RLFTF

partnership

Relief and NeuroRx Announce Partnership for Global Commercialization of RLF-100™ and Selection of Commercial Partners

RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) (" Relief" or the " Company") and NeuroRx, Inc. today announced the completion of their partnership agreement for the commercialization of RLF-100™(Aviptadil) worldwide. The

RHEA-AI

neutral

09/15/20 1:30 AM

OTC : RLFTF

Relief Reports Half-Year 2020 Results

RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) (" Relief" or the " Company"), a biopharmaceutical company with its lead compound RLF-100 (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today announced

RHEA-AI

neutral

Prev 1 2 3 4 5 6 Next